Goulielmaki, M.; Stokidis, S.; Anagnostou, T.; Voutsas, I.F.; Gritzapis, A.D.; Baxevanis, C.N.; Fortis, S.P.
Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer. Int. J. Mol. Sci. 2023, 24, 5954.
https://doi.org/10.3390/ijms24065954
AMA Style
Goulielmaki M, Stokidis S, Anagnostou T, Voutsas IF, Gritzapis AD, Baxevanis CN, Fortis SP.
Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer. International Journal of Molecular Sciences. 2023; 24(6):5954.
https://doi.org/10.3390/ijms24065954
Chicago/Turabian Style
Goulielmaki, Maria, Savvas Stokidis, Theodoros Anagnostou, Ioannis F. Voutsas, Angelos D. Gritzapis, Constantin N. Baxevanis, and Sotirios P. Fortis.
2023. "Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer" International Journal of Molecular Sciences 24, no. 6: 5954.
https://doi.org/10.3390/ijms24065954
APA Style
Goulielmaki, M., Stokidis, S., Anagnostou, T., Voutsas, I. F., Gritzapis, A. D., Baxevanis, C. N., & Fortis, S. P.
(2023). Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer. International Journal of Molecular Sciences, 24(6), 5954.
https://doi.org/10.3390/ijms24065954
